Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases

NCT02859415 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

3

Enrollment

NIH

Sponsor class

Stopped Slow/Insufficient accrual

Conditions

Esophageal Neoplasms
Lung Neoplasms
Mesothelioma
Thymus Neoplasms
Neoplasms, Germ Cell and Embryonal

Interventions

DRUG: Mithramycin

Sponsor

National Cancer Institute (NCI)